Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:59
|
Bid Volume |
Ask
02/27/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
17.51
-0.17
(
-0.96% )
|
17.50
|
3,700 |
17.51
|
900 |
Analysis date: 24.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 15.07.2025.
Interest
Weak
Weak
Two stars since 24.02.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 24.02.2026 at a price of 18.20.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 09.01.2026.
4wk Rel Perf
15.12%
15.12%
The four-week dividend-adjusted overperformance versus SP500 is 15.12%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 15.07.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.10%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 9.33%.
Mkt Cap in $bn
1.30
1.30
With a market capitalization <$2bn, MOONLAKE IMMUNOTHERAPEUTICS is considered a small-cap stock.
G/PE Ratio
0.05
0.05
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-6.56
-6.56
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
0.35%
0.35%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
9
9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
29
29
For 1% of index variation, the stock varies on average by 0.29%.
Correlation
0.04
0.04
Stock movements are totally independent of index variations.
Value at Risk
17.29
17.29
The value at risk is estimated at USD 17.29. The risk is therefore 95.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025